Treats severe asthma aged 18 years and older with an eosinophilic phenotype. Sold as Cinqair. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Reslizumab (sold as Cinqair), first approved Mar 23, 2016, with 0 new uses approved and 0 published complete response letters.
| Cinqair | Part B | $7.5M | -13% | 276 |
| Cinqair | Part D | $964K | +0% | 30 |
| Expression of TSLP Isoforms in AsthmaAsthma Atopic, Asthma Severe Persistent Uncontrolled · Medical University of Warsaw | — | Recruiting | Aug 26, 2026 |
| Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic AgentsHypereosinophilic Syndrome · National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | Recruiting | Jun 27, 2024 |
| Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) StudyAsthma · National Jewish Health | Phase 2 | Recruiting | Oct 28, 2016 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Mar 23, 2016 | CinqairBLA 761033 · New molecular entity | Teva Respiratory LLC | 1 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
